Madri­gal seeks ac­cel­er­at­ed ap­proval for ex­per­i­men­tal NASH treat­ment a week af­ter In­ter­cept re­jec­tion

Madri­gal Phar­ma­ceu­ti­cals kicked off the reg­u­la­to­ry re­view process for its ex­per­i­men­tal NASH treat­ment as it pur­sues the first FDA ap­proval to treat the de­bil­i­tat­ing and some­times fa­tal liv­er dis­ease for which no oth­er ther­a­pies ex­ist.

Madri­gal an­nounced Fri­day that it be­gan a rolling sub­mis­sion for ac­cel­er­at­ed ap­proval of resme­tirom as a treat­ment for NASH with liv­er fi­bro­sis, based on da­ta show­ing that the thy­roid hor­mone be­ta-re­cep­tor ag­o­nist met both pri­ma­ry sur­ro­gate end­points in a Phase III tri­al. The com­pa­ny said it sub­mit­ted the ma­jor­i­ty of its NDA, and it plans to file the re­main­ing com­po­nents in Ju­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER